Bioverativ inks $100M gene therapy deal with Oxford BioMedica
British gene therapy company Oxford BioMedica has inked a deal worth up to $100 million to supply materials to Bioverativ, the gene therapy maker who just got snatched by Sanofi for $11.6 billion.
Oxford BioMedica only got $5 million up front, but could get milestone payments of $100 million down the road, along with royalties on sales of the hemophilia treatments Bioverativ is developing.
Oxford BioMedica is not new to the gene therapy game — the public company was listed in London in 1996. But thanks to Spark Therapeutics, which got the FDA OK to treat blindness with gene therapy drug Luxturna late last year, the entire field is now coming of age. And now Oxford BioMedica is cashing in.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.